Table 2.
Fractions of end-joined products mediated by 2-bp (AG) or 3-bp (CAG) repeats at the ends of substrates
| DNA substrates | siRNA treatments | No. of EJ products used repeats at the ends of substrates | No. of total EJ products sequenced | Percentage | P-valuea |
|---|---|---|---|---|---|
| pUC18-2bp-repeat | |||||
| Non-silencing control siRNA | 12 | 19 | 63 | ||
| Lig1 siRNA | 15 | 22 | 68 | 0.735 | |
| Lig3 siRNA | 6 | 23 | 26 | 0.016 | |
| Lig4 siRNA | 12 | 16 | 75 | 0.452 | |
| pUC18-3bp-repeat | |||||
| Non-silencing control siRNA | 13 | 21 | 62 | ||
| Lig1 siRNA | 9 | 19 | 47 | 0.356 | |
| Lig3 siRNA | 7 | 22 | 32 | 0.048 | |
| Lig4 siRNA | 11 | 20 | 55 | 0.654 | |
aComparisons of the fraction of end joined products mediated by 2- or 3-bp repeats at the ends of substrates in HTD114 nuclear extracts with siRNA treatments against different ligases to the control siRNA were done with contingency tables. Significant levels were determined with chi-squared test.